Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design (Hylenex-ED)
This is an observational study examining the workflow dynamics and training requirements that support effective use of subcutaneous hydration delivery (a newly FDA approved Baxter product) compared to standard intravenous hydration/medication delivery. Emergency departments already using both Subcutaneous Recombinant Human Hyaluronidase and standard IV hydration will be enrolled. Patients will be receiving the hydration method selected by their emergency department physician and the investigators will then observe:
- Efficiency of patient care and treatment areas
- Safety of patient care and treatment areas
- Support Service processes that impact patient flow
- Time to conversion from dehydration to hydration'
- Rate of complications
- Staff satisfaction with Subcutaneous hydration vs. Intravenous hydration
- Patient satisfaction with Subcutaneous hydration vs. Intravenous hydration
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design|
- elapsed time in Emergency Department [ Time Frame: elapsed time in the Emergency Department is measured from the point a patient enters until they leave ] [ Designated as safety issue: No ]it is hypothesized patients hydrated via Subcutaneous Recombinant Human Hyaluronidase will progress to discharge from the emergency department faster then will patients hydrated via I.V.
|Study Start Date:||November 2010|
|Study Completion Date:||February 2011|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|